Re: [TMIC] stem cell treatment for spinal cord lesionsSure hope your husband gets in the trial. Good luck. Janice
From: Emily Sent: Monday, November 15, 2010 1:10 PM To: tmic-list@eskimo.com Subject: RE: [TMIC] stem cell treatment for spinal cord lesions My husband is currently in the 3-12 month window..he was diagnosed on September 2nd with TM T-7-11. We have contacted my husband's neurologist to see if they could get him in this trial in Switzerland. We are awaiting a reply. -------------------------------------------------------------------------------- From: Dalton Garis [mailto:malugss...@gmail.com] Sent: Monday, November 15, 2010 1:39 PM To: fr...@franksheldon.com; tmic-list@eskimo.com; Garis, Brooks (Darien, CT) Subject: Re: [TMIC] stem cell treatment for spinal cord lesions Could it be the miracle mankind has been waiting for? Just imagine if this thing works! Dalton -------------------------------------------------------------------------------- From: <fr...@franksheldon.com> Date: Mon, 15 Nov 2010 14:10:01 +0000 To: <tmic-list@eskimo.com> Subject: [TMIC] stem cell treatment for spinal cord lesions Resent-From: <tmic-list@eskimo.com> Resent-Date: Mon, 15 Nov 2010 06:10:06 -0800 News release: StemCells, Inc. Files to Conduct Neural Stem Cell Trial in Chronic Spinal Cord Injury PALO ALTO, Calif., Nov 15, 2010 (GlobeNewswire via COMTEX) --StemCells, Inc. (Nasdaq:STEM) announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC(R) purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury."With this filing we have taken a tangible step to broaden the clinical development of our HuCNS-SC product candidate beyond the brain and into the spinal cord," said Martin McGlynn, President and CEO of StemCells, Inc. "This exciting initiative is supported by extensive preclinical research demonstrating the ability of our proprietary cells to restore lost motor function when transplanted in the chronic spinal cord injury setting. The prospect of extending the treatment window to months or longer following injury would mean that a much larger population of injured patients could potentially benefit from such an approach."
